Immunocore (NASDAQ:IMCR) Receives Buy Rating from HC Wainwright

Immunocore (NASDAQ:IMCR - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $100.00 price objective on the stock. HC Wainwright's price target suggests a potential upside of 241.88% from the company's previous close. HC Wainwright also issued estimates for Immunocore's FY2027 earnings at $1.10 EPS, FY2028 earnings at $4.46 EPS and FY2029 earnings at $7.96 EPS.

A number of other research analysts also recently commented on IMCR. Mizuho downgraded shares of Immunocore from an "outperform" rating to a "neutral" rating and decreased their price objective for the company from $72.00 to $38.00 in a research report on Monday, November 11th. Morgan Stanley reissued an "equal weight" rating and set a $35.00 price target (down previously from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 price objective on shares of Immunocore in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Immunocore has an average rating of "Moderate Buy" and an average target price of $65.64.

Immunocore Stock Up 1.3 %

Shares of NASDAQ:IMCR traded up $0.37 during trading on Friday, hitting $29.25. 249,624 shares of the company were exchanged, compared to its average volume of 227,774. Immunocore has a fifty-two week low of $27.69 and a fifty-two week high of $67.30. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -30.79 and a beta of 0.77. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The firm has a fifty day moving average price of $30.09 and a two-hundred day moving average price of $31.76.

Remove Ads

Institutional Investors Weigh In On Immunocore

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP grew its stake in shares of Immunocore by 10.5% in the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company's stock valued at $219,430,000 after acquiring an additional 668,382 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Immunocore by 3.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock worth $197,657,000 after purchasing an additional 200,373 shares during the period. FMR LLC raised its position in shares of Immunocore by 0.5% in the third quarter. FMR LLC now owns 4,836,040 shares of the company's stock valued at $150,546,000 after buying an additional 23,436 shares in the last quarter. Primecap Management Co. CA boosted its stake in shares of Immunocore by 8.0% in the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock valued at $78,722,000 after buying an additional 196,530 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Immunocore by 1.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company's stock worth $64,533,000 after buying an additional 29,832 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.